VEG-HM421-100μg / 询价
VEG-HM421-500μg / 询价
VEG-HM421-500μgx2 / 询价
Human VEGF121 Protein
Recombinant Human VEGF121 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Ala27-Arg147 [Accession | P15692-9].
The protein has a predicted MW of 17 kDa. Due to glycosylation, the protein migrates to 18 kDa and 22-25 kDa under reduced (R) condition, 30 kDa and 32-40 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS,250mM Arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human VEGF121 on Bis-Tris PAGE under reduced (R) condition and Non reducing (N) condition. The purity is greater than 95%.
Immobilized Human VEGF121, His Tag at 2μg/ml (100ul/Well). Dose response curve for Biotinylated Human VEGFR1, His Tag with the EC50 of 42ng/ml determined by ELISA.
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189.
VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609
(1)Rosen, L. S. VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances[J]. The Oncologist, 2005, 10(6):382-391.
